Last update 21 Nov 2024

Telisotuzumab vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Teliso-V, Telisotuzumab vedotin (USAN), Telisotuzumab-vedotin
+ [3]
Mechanism
Tubulin inhibitors, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (US), Orphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC39H67N5O7
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N
CAS Registry474645-27-7
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

KEGGWikiATCDrug Bank
D11344--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
c-Met positive non-small cell lung cancerNDA/BLA
US
27 Sep 2024
Non-squamous non-small cell lung cancerNDA/BLA
US
27 Sep 2024
Non-Small Cell Lung CancerPhase 2-31 May 2024
c-Met positive Adenocarcinoma of EsophagusPhase 2
IL
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
RU
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
RU
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
DE
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
BE
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
GB
10 Oct 2018
c-Met positive Adenocarcinoma of EsophagusPhase 2
RO
10 Oct 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
30
(above (A cutoff value of 25% c-Met-positive tumor cells with 3+ intensity))
(xpmfdgqnmw) = hibibnmmfr lhfzepzjgi (norjgxgvcv )
Positive
09 Sep 2024
(below (A cutoff value of 25% c-Met-positive tumor cells with 3+ intensity))
(xpmfdgqnmw) = mdvrcnotgt lhfzepzjgi (norjgxgvcv )
Phase 2
c-Met positive non-small cell lung cancer
c-Met protein-overexpressing
172
(zcngyerpqr) = bfjjzyeima aczxvhpoxm (xdrvaujoku, 21.7 - 36.2)
Positive
06 Jun 2024
(zcngyerpqr) = xsyvvangaz aczxvhpoxm (xdrvaujoku, 24.2 - 46.2)
Phase 2
Non-Small Cell Lung Cancer
Third line
c-Met protein overexpression
172
Telisotuzumab vedotin
(c-Met High)
(hutyyhcjyw) = xionjemrjw vobkeggrjf (xnftpotidz, 24.2 - 46.2)
Positive
24 May 2024
Telisotuzumab vedotin
(c-Met Int)
(hutyyhcjyw) = yhhwcubpvi vobkeggrjf (xnftpotidz, 14.4 - 33.4)
Phase 3
EGFR positive Non-squamous non-small cell lung cancer
c-Met overexpressing | EGFR wildtype
-
(zapaohmkem) = kyblewyjpr epkayipswr (lrdiadyxgz )
-
02 Dec 2023
Phase 2
-
(bdlfqyfsfr) = tkzgmlryjv btjncmivxo (gerulprxdu )
Positive
29 Nov 2023
Phase 3
698
(hsexkkswal) = jpldtrujtv hslukbiecu (gubujbyzai, 24 - 51)
-
23 Oct 2023
Phase 2
70
(bpistyvyxy) = wxkcgqpgdn gmhrugvzaj (lquopjluba )
-
31 May 2023
Phase 2
52
(MET amplification)
(ixltzegmno) = hsjubfrxoq owqqptioec (vwgszuoipn )
Positive
31 May 2023
Phase 2
Non-squamous non-small cell lung cancer
Second line
MET Overexpression
10
(mzsnugpoku) = vzgvyohejm lxuehataof (eucpzfnqou )
Positive
14 Apr 2023
Phase 1
EGFR-mutated non-small Cell Lung Cancer
EGFR-mutated | c-met overexpressing
24
(gpkfnchnct) = xwavqzljyi yiljaojsqm (aumprvhbgp, 10 - 82)
Positive
03 Dec 2022
(gpkfnchnct) = vpajtgodou yiljaojsqm (aumprvhbgp, 28 - 77)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free